Vesalius Biocapital

Managing Partner Stéphane Verdood, a co-founder, leads the investment committee. He works alongside Partner Anne Portwich and a team of investment professionals based in Luxembourg and Brussels. The firm integrates operating partners with pharmaceutical R&D backgrounds into the due-diligence process, giving clinical judgment equal weight to financial analysis.

The firm leans heavily on direct relationships with European research universities and academic medical centers, particularly in Belgium, France, Germany, and the Netherlands. Many portfolio companies originate as university spin-outs where Vesalius can structure the first institutional round. The Toronto office adds a second sourcing channel by identifying North American platforms seeking a European clinical-development partner.

Vesalius invests from seed and Series A through growth-stage rounds, occasionally participating in later-stage crossovers when a portfolio company approaches a clinical or regulatory inflection point. The firm can lead, co-lead, or syndicate, and has supported companies from preclinical proof-of-concept through Phase II clinical data readouts.

The firm makes direct equity investments into life sciences companies. It does not operate a fund-of-funds program, though its limited partners include fund-of-funds vehicles such as the European Investment Fund. Vesalius structures its own flagship fund series for direct investing, with Vesalius Biocapital III closing in 2019.

Vesalius restricts itself to human life sciences — biopharma, medical devices, and diagnostics. It does not invest in healthcare IT, consumer wellness, provider services, or animal health. Within biopharma, the firm has shown a preference for small-molecule and biologic platforms over digital therapeutics.

Vesalius Biocapital is a traditional private equity and venture capital firm managing third-party institutional capital, not a single-family office. It operates a classic GP-LP fund structure with a diversified limited-partner base that includes supranational entities, pension funds, and family offices.

The Toronto office provides European portfolio companies with access to North American clinical-trial infrastructure, regulatory consultants, and co-investor relationships without requiring the firm to raise a separate US-dollar fund. This transatlantic structure is designed to help companies design FDA-acceptable trial protocols and open US investigative sites while still operating from a European cost base.